IRIS
MURDACA, GIUSEPPE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 13.427
Totale 13.427
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 13.427
Totale 13.427
Salva come PNG Salva come JPEG
Città #
Genova 9.464
Rapallo 1.398
Genoa 1.269
Vado Ligure 1.249
Bordighera 47
Totale 13.427
Salva come PNG Salva come JPEG
Nome #
Non-antigen-specific CD8(+) T suppressor lymphocytes in diseases characterized by chronic immune responses and inflammation. 233
Infection risk associated with anti-TNF-α agents: A review 173
A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer 157
Treatment Algorithms for Systemic Sclerosis According to Experts 152
Autoimmune central diabetes insipidus in a patient with ureaplasma urealyticum infection and review on new triggers of immune response. 150
Vaccine-preventable infections in Systemic Lupus Erythematosus 149
Soluble HLA-G and HLA-A,-B,-C serum levels in patients with allergic rhinitis 144
The antiphospholipid syndrome: from pathophysiology to treatment 144
Beneficial effects of long-term treatment with bosentan on the development of pulmonary arterial hypertension in patients with systemic sclerosis 144
TNF-α gene polymorphisms: association with disease susceptibility and response to anti-TNF-α treatment in psoriatic arthritis 143
Autoimmune intrahepatic cholangiopathy associated with antiphospholipid antibody syndrome 141
Immunogenicity of infliximab and adalimumab: What is its role in hypersensitivity and modulation of therapeutic efficacy and safety? 140
Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications 139
Soluble HLA-G molecule in patients with perennial allergic rhinitis. 134
Immunoregulatory Role of HLA-G in Allergic Diseases 132
General surgery, translational lymphology and lymphatic surgery 132
Allergen-driven HLA-G expression and secretion in peripheral blood mononuclear cells from allergic rhinitis patients 131
Adult iatrogenic Cushing's syndrome induced by topical skin corticosteroid misuse 131
Soluble serum HLA-G and HLA-A, -B, -C molecules in patients with seasonal allergic rhinitis exposed to pollens. 130
Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy. 130
Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment: potential role as markers of response to antiviral therapy 127
Plicometer skin test: a new technique for the evaluation of cutaneous involvement in systemic sclerosis. 126
Behavior of serum human major histocompatibility complex class I antigen levels in human immunodeficiency virus-infected patients during antiretroviral therapy: correlation with clinical outcome 124
Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events 121
Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis 121
Low expression of inhibitory natural killer receptors in CD8 cytotoxic T lymphocytes in long-term non-progressor HIV-1-infected patients 119
Potential use of TNF-α inhibitors in systemic sclerosis. 119
Vdelta1 T lymphocytes producing IFN-gamma and IL-17 are expanded in HIV-1-infected patients and respond to Candida albicans 118
Serum adiponectin levels in patients with pollen-induced allergic rhinitis 118
Intima-media thickness: a marker of accelerated atherosclerosis in women with systemic lupus erythematosus 118
Sublingual immunotherapy reduces soluble HLA-G and HLA-A,-B,-C serum levels in patients with allergic rhinitis. 117
Free radicals and endothelial dysfunction: potential positive effects of TNF-α inhibitors. 117
Serum interleukin-17 levels are related to clinical severity in allergic rhinitis 116
Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis 116
Hypoadiponectinemia in lipodystrophic HIV individuals: a metabolic marker of subclinical cardiac damage 116
Phase 4 randomized trial of intradermal low-antigen-content inactivated influenza vaccine versus standard-dose intramuscular vaccine in HIV-1-infected adults. 115
Postexposure HIV prophylaxis regimen. 114
Two year sublingual immunotherapy affects serum leptin 113
Current views on diagnostic approach and treatment of lymphedema 113
Effects of TNF-α inhibitors upon the mechanisms of action of VEGF. 112
Use of leflunomide plus TNF-α inhibitors in rheumatoid arthritis 111
Drug-induced aminotransferase alterations during antiretroviral HIV post-exposure prophylaxis 110
Anti-tumour necrosis factor-a treatment with infliximab for disseminated granuloma annulare 110
Genetic factors and systemic sclerosis 110
A rare hepatic mass in an Italian resident 110
Body mass index in Th1 and Th2 diseases. 109
Serum vascular endothelial growth factor and sublingual immunotherapy 109
Significant NK cell activation associated with decreased cytolytic function in peripheral blood of HIV-1 infected patients 108
Adipokines and sublingual immunotherapy: preliminary report. 107
The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases 107
Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: Current views upon safety and immunogenicity. 107
Hepatic safety and postexposure prophylaxis 107
Serum IL-17 after one course of sublingual immunotherapy in allergic rhinitis to birch 106
Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection: A case control study 106
Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study). 106
Apoptosis in the Homeostasis of the Immune System and in Human Immune Mediated Diseases 105
Pharmacogenetics of etanercept: role of TNF-α gene polymorphisms in improving its efficacy 105
ACUTE CARDIAC FAILURE AND IGA NEPHROPATHY: AN UNCOMMON SLE ONSET 104
Efficacy and safety of etanercept in chronic immune-mediated disease. 103
Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study 103
Characteristics of current heart failure patients admitted to internal medicine vs. cardiology hospital units: the VASCO study 102
Lymphatic microsurgery to treat lymphedema: techniques and indications for better results. 101
Current recommendation to reduce the burden of bacterial and viral infections in patients affected by systemic lupus erythematosus 101
Remission of Brucella endocarditis in a patient with mitral valve mechanical prosthesis by antibiotic therapy alone: a case report 101
Update upon the infection risk in patients receiving TNF alpha inhibitors 101
Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety. 100
Update upon efficacy and safety of TNF-α inhibitors. 100
An Uncommon Presentation of Pancreatic Carcinoma 100
Endothelial dysfunction in rheumatic autoimmune diseases. 100
A case of transposition of the great arteries in a female infant of a HIV-1 infected woman. Potential teratogenic effect of antiretroviral drugs. 100
Soluble HLA-G serum levels in patients with the Acquired Immunodeficiency Syndrome affected by different AIDS-defining conditions before and after anti-retroviral treatment 99
Differential disappearance of inhibitory natural killer cell receptors during HAART and possible impairment of HIV-1-specific CD8 cytotoxic T lymphocytes. 99
Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study 99
Esophageal baseline impedance levels allow the identification of esophageal involvement in patients with systemic sclerosis 98
Recurrent intestinal perforation associated with thrombosis of inferior vena cava: uncommon presentation of antiphospholipid syndrome. 97
Emerging biologic drugs for the treatment of rheumatoid arthritis 96
Determination of lymphotoxin-α levels in patients with psoriatic arthritis undergoing etanercept treatment 96
Behavior of non-classical soluble HLA class G antigens in human immunodeficiency virus 1-infected patients before and after HAART: comparison with classical soluble HLA-A, -B, -C antigens and potential role in immune-reconstitution. 94
HLA-G Expressing Immune Cells in Immune Mediated Diseases 94
Nocturia: an uncommon presentation of lower-limb lymphedema. 93
Interleukin-2 therapy in patients with HIV infection 93
HLA-G expression in gastric carcinoma: clinicopathological correlations and prognostic impact 93
Differential diagnosis in recurrent intestinal perforation: chronic inflammatory disease with intestinal lymphedema or antiphospholipid syndrome? 92
Effects of antagomiRs on different lung diseases in human, cellular, and animal models 92
Pharmacogenetics and future therapeutic scenarios: what affects the prediction of response to treatment with etanercept? 91
Regulation of gammadelta T cell survival by soluble HLA-I: Involvement of CD8 and activating killer Ig-like receptors. 90
Selective TNF-α inhibitor-induced injection site reactions. 90
The impaired NK cell cytolytic function in viraemic HIV-1 infection is associated with a reduced surface expression of Natural Cytotoxicity Receptors (NKp46, NKp30 and NKp44) 88
Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART 87
Immunogenicity of infliximab and adalimumab 86
Emerging role of vitamin D in autoimmune diseases: An update on evidence and therapeutic implications 86
Serum vascular endothelial growth factor in allergic rhinitis and systemic lupus erythematosus 84
DECAY OF HIV-1 2LTR DNA IN INFECTED INDIVIDUALS AFTER THREE TO EIGHT YEARS OF SUSTAINED CONTROL OF VIREMIA. 82
Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events. 81
Virological markers in HIV-1 infected patients 81
Migration of V delta 1 and V delta 2 T cells in response to CXCR3 and CXCR4 ligands in healthy donors and HIV-1-infected patients: competition by HIV-1 Tat. 80
Antiphospholipid syndrome and reversible posterior leukoencephalopathy syndrome. 79
Prevention of Lymphatic Injuries in Surgery. 78
ENDOTHELIAL DYSFUNCTION IN PSORIATIC ARTHRITIS: EVALUATION BY ENDOTHELIAL-DEPENDENT FLOW-MEDIATED DILATION AND CORONARY FLOW RESERVE 77
Modifications of immunological and neuro-endocrine parameters induced by antiorthostatic bed-rest in human healthy volunteers. 76
Totale 11.109
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.777
article - articoli 47.777
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 95.554
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.345 0 0 0 0 0 363 465 240 283 534 365 95
2020/20211.366 63 76 91 146 136 183 155 115 105 108 95 93
2021/20221.701 43 116 123 190 56 126 78 406 101 154 70 238
2022/20231.671 143 105 28 163 298 285 10 145 261 15 185 33
2023/20241.007 39 149 19 133 66 149 95 80 54 15 63 145
2024/20251.401 111 219 110 236 418 307 0 0 0 0 0 0
Totale 13.831